Nitrosamine impurities in medicines: List of medicines impacted
Find information on medicines that are impacted due to potential nitrosamine impurities
Necessary actions have been taken to stop the supply or remove products that may pose safety risks to patients from the Singapore market. To ensure patients’ continued access to essential medicines, HSA had also temporarily allowed continued supply of certain medicines that may contain nitrosamine impurities above acceptable levels while companies make the necessary changes to eliminate or reduce the nitrosamines to acceptable levels. The list of medicines impacted are listed below.
|
Medicine
|
Use
|
Link(s) to further information
|
|
Acyclovir
|
Chickenpox, shingles, herpes simplex virus infection
|
27 Apr 2022 – Product recall
1 Aug 2022 – Product recall
|
|
Angiotensin II receptor blockers (ARBs) e.g. candesartan, irbesartan, losartan, olmesartan, valsartan
|
High blood pressure
|
28 Mar 2019 – Product recall
|
|
Metformin
|
Type 2 diabetes mellitus
|
4 Dec 2019 – Product recall
|
|
Ranitidine
|
Indigestion, heartburn, gastric ulcers
|
16 Sep 2019 – Product recall
|
|
Rifampicin
|
Tuberculosis
|
23 Apr 2021 – Update on nitrosamine impurity in rifampicin products
|
|
Salbutamol
|
Asthma, chronic bronchitis, emphysema
|
9 Dec 2021 – Product recall
|
| Sitagliptin |
Type 2 diabetes mellitus |
2 Nov 2022- Update on nitrosamine impurity in sitagliptin products |
|
Varenicline
|
Smoking cessation
|
16 Nov 2021 – Product recall
|